Search results for: 'transform eu'

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

27 Nov 2024  |  Global  |  Market Research

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

Gen AI-based Solutions are Driving Transformational Growth across the Payer and Provider Ecosystem as Organizations Move from Identification to Implementation

Infographics

×

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journey. Gen AI seamlessly syncs with existing tools/IT ...

24 Aug 2021  |  North America  |  Market Research

US and EU Biotech Industry VC Investment Growth Opportunities

Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

Infographics

×

With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

With this research service, Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the European Union and UK COVID-19 vaccine and therapeutics market. The report analyzes COVID-19 vaccines and therapeutics in development and delves into supply chain considerations and requirements to manage distribution. Importantly, t...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

Southeast Asia (SEA) is emerging as the gold mine for both local and international healthcare vendors. Within SEA, Malaysia, Singapore, and Indonesia still have unexplored and under-served markets providing boundless opportunities for healthcare vendors with innovative products and services. To be able to capitalize on the market, medical device ma...

12 Aug 2020  |  North America  |  Market Research

Strategic Commercial Partnerships Transforming the Global Biobanking Market, 2020–2026

Precision Medicine Applications and Value-based Data Pricing with Pharma and Health-tech to Trigger Market Growth

Infographics

×

The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compou...

Overall Impact of Biomanufacturing Technology Innovations Impact on Unmet Needs Pharmaceutical companies perceive analytical services as important. There is a need for a robust platform that enables the provision of such services. Pharma firms are outsourcing crucial processes and are utilizing services such as analytics, research, process developm...

The Philippines is a part of the Association of Southeast Asian Nations (ASEAN) community and one of the fastest growing healthcare markets in the region. With regard to healthcare, the Philippine Government has been looking at ways to achieve 100% enrolment to PhilHealth by 2020. One of the means is by mandating all Filipinos to enrol to PhilHealt...